2013-01-08 11:53:12 - Factors like easy availability, lower cost of whole genome sequencing (WGS) and widely publicized positive impact WGS has played in diagnosing cancer will make cancer diagnosis through WGS a profitable venture for players.
As per the new research report by RNCOS, “US Personalized Cancer Genome Sequencing Market”, a huge potential market lays untapped for the players in the whole genome sequencing (WGS) business. Buoyed by the positive opinion created from media stories about the various successful personalized cancer therapies that were aided by WGS, a lot of Americans suffering from cancer are interested in availing the services, despite the high costs. Most of these costs involve the fees of experts, oncologists and are not covered by insurance. Still, around 881,667 US citizens stand as potential customers, willing to pay out-of-pocket for personalized cancer WGS services.
This figure offers immense opportunities for the players that provide personalized cancer WGS services. Personalized diagnosis of patient’s genome
facilitates personalized cancer treatment and saves on unnecessary drug-related complications and costs, making it an attractive option for both the patient and health care provider. This sector thus stands responsible for catering to a huge population of cancer patients that present a soaring potential market. Players need to expand their facilities, work on reducing turnaround time, and associated costs to cater to an ever increasing customer base.
Overall the report is an outcome of an extensive research and in-depth analysis of the current status and expected position of the US market for personalized WGS intended for diagnosing cancer. It evaluates the current status and future potential of the market and focuses on the strengths and weaknesses of the market players.
Moreover, the report projects the future size of the market till 2016. In this context, it illustrates the market drivers, key developments, and restraints that may impact the market in an effective manner. A brief description of the regulatory environment has also been provided in the report.
For FREE SAMPLE of this report visit: www.rncos.com/Report/IM453.htm
Some of our Related Reports are:
- Brazil Healthcare - New Opportunities for Growth ( www.rncos.com/Report/IM451.htm
- US Non-Invasive Prenatal Diagnostics - Market Insight ( www.rncos.com/Report/IM450.htm
- US Cardiac Device Market Analysis ( www.rncos.com/Report/IM441.htm
- US Clinical Laboratory Testing Market Assessment ( www.rncos.com/Report/IM442.htm
- Global Genetic Testing Market Forecast to 2015 ( www.rncos.com/Report/IM445.htm
Check Related REPORTS on: www.rncos.com/Healthcare_Industry.htm
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.